Starpharma Holdings Limited (SPL.AX) Stock Competitors & Peer Comparison
See (SPL.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SPL.AX | A$0.71 | +2.16% | 294.6M | 111.11 | A$0.01 | N/A |
| CSL.AX | A$118.37 | +2.58% | 55B | 12.34 | A$9.30 | +3.71% |
| TLX.AX | A$17.02 | +5.26% | 5.6B | -598.34 | -A$0.03 | N/A |
| MSB.AX | A$2.04 | +4.62% | 2.5B | -13.15 | -A$0.15 | N/A |
| NEU.AX | A$17.65 | +6.33% | 2.3B | 75.56 | A$0.23 | N/A |
| PYC.AX | A$1.68 | +1.82% | 982.4M | -36.95 | -A$0.05 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | 6.14 | A$0.10 | N/A |
| CUV.AX | A$10.42 | +0.68% | 518.2M | 15.96 | A$0.64 | +0.49% |
| RAC.AX | A$2.20 | -1.35% | 435.3M | -107.25 | -A$0.02 | N/A |
| OCC.AX | A$0.72 | -0.69% | 161M | -26.85 | -A$0.03 | N/A |
Stock Comparison
SPL.AX vs CSL.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, CSL.AX has a market cap of 55B. Regarding current trading prices, SPL.AX is priced at A$0.71, while CSL.AX trades at A$118.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas CSL.AX's P/E ratio is 12.34. In terms of profitability, SPL.AX's ROE is -0.16%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, SPL.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check CSL.AX's competition here
SPL.AX vs TLX.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, TLX.AX has a market cap of 5.6B. Regarding current trading prices, SPL.AX is priced at A$0.71, while TLX.AX trades at A$17.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas TLX.AX's P/E ratio is -598.34. In terms of profitability, SPL.AX's ROE is -0.16%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, SPL.AX is more volatile compared to TLX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check TLX.AX's competition here
SPL.AX vs MSB.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, MSB.AX has a market cap of 2.5B. Regarding current trading prices, SPL.AX is priced at A$0.71, while MSB.AX trades at A$2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas MSB.AX's P/E ratio is -13.15. In terms of profitability, SPL.AX's ROE is -0.16%, compared to MSB.AX's ROE of -0.14%. Regarding short-term risk, SPL.AX is more volatile compared to MSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check MSB.AX's competition here
SPL.AX vs NEU.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, NEU.AX has a market cap of 2.3B. Regarding current trading prices, SPL.AX is priced at A$0.71, while NEU.AX trades at A$17.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas NEU.AX's P/E ratio is 75.56. In terms of profitability, SPL.AX's ROE is -0.16%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, SPL.AX is more volatile compared to NEU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check NEU.AX's competition here
SPL.AX vs PYC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, PYC.AX has a market cap of 982.4M. Regarding current trading prices, SPL.AX is priced at A$0.71, while PYC.AX trades at A$1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas PYC.AX's P/E ratio is -36.95. In terms of profitability, SPL.AX's ROE is -0.16%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, SPL.AX is more volatile compared to PYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check PYC.AX's competition here
SPL.AX vs OPT.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas OPT.AX's P/E ratio is 6.14. In terms of profitability, SPL.AX's ROE is -0.16%, compared to OPT.AX's ROE of +0.44%. Regarding short-term risk, SPL.AX is more volatile compared to OPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check OPT.AX's competition here
SPL.AX vs CUV.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, CUV.AX has a market cap of 518.2M. Regarding current trading prices, SPL.AX is priced at A$0.71, while CUV.AX trades at A$10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas CUV.AX's P/E ratio is 15.96. In terms of profitability, SPL.AX's ROE is -0.16%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, SPL.AX is more volatile compared to CUV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check CUV.AX's competition here
SPL.AX vs RAC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, RAC.AX has a market cap of 435.3M. Regarding current trading prices, SPL.AX is priced at A$0.71, while RAC.AX trades at A$2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas RAC.AX's P/E ratio is -107.25. In terms of profitability, SPL.AX's ROE is -0.16%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, SPL.AX is more volatile compared to RAC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check RAC.AX's competition here
SPL.AX vs OCC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, OCC.AX has a market cap of 161M. Regarding current trading prices, SPL.AX is priced at A$0.71, while OCC.AX trades at A$0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas OCC.AX's P/E ratio is -26.85. In terms of profitability, SPL.AX's ROE is -0.16%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, SPL.AX is more volatile compared to OCC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check OCC.AX's competition here
SPL.AX vs ATH.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ATH.AX has a market cap of 125.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ATH.AX trades at A$0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ATH.AX's P/E ratio is -338.24. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, SPL.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check ATH.AX's competition here
SPL.AX vs DXB.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, DXB.AX has a market cap of 123.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while DXB.AX trades at A$0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas DXB.AX's P/E ratio is -4.11. In terms of profitability, SPL.AX's ROE is -0.16%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, SPL.AX is more volatile compared to DXB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check DXB.AX's competition here
SPL.AX vs RCE.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, RCE.AX has a market cap of 117.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while RCE.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas RCE.AX's P/E ratio is -4.45. In terms of profitability, SPL.AX's ROE is -0.16%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, SPL.AX is more volatile compared to RCE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check RCE.AX's competition here
SPL.AX vs ACW.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ACW.AX has a market cap of 115.2M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ACW.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ACW.AX's P/E ratio is -5.38. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, SPL.AX is more volatile compared to ACW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ACW.AX's competition here
SPL.AX vs PAA.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, SPL.AX's ROE is -0.16%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, SPL.AX is more volatile compared to PAA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check PAA.AX's competition here
SPL.AX vs ILA.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ILA.AX has a market cap of 95M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ILA.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ILA.AX's P/E ratio is -12.18. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, SPL.AX is more volatile compared to ILA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ILA.AX's competition here
SPL.AX vs IMM.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, IMM.AX has a market cap of 78.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while IMM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas IMM.AX's P/E ratio is -0.93. In terms of profitability, SPL.AX's ROE is -0.16%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, SPL.AX is more volatile compared to IMM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check IMM.AX's competition here
SPL.AX vs ALA.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ALA.AX has a market cap of 74.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ALA.AX's P/E ratio is -8.72. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, SPL.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ALA.AX's competition here
SPL.AX vs ATX.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ATX.AX has a market cap of 74.4M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ATX.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ATX.AX's P/E ratio is -8.38. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ATX.AX's ROE of -0.19%. Regarding short-term risk, SPL.AX is more volatile compared to ATX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ATX.AX's competition here
SPL.AX vs PAR.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, PAR.AX has a market cap of 71.5M. Regarding current trading prices, SPL.AX is priced at A$0.71, while PAR.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas PAR.AX's P/E ratio is -2.26. In terms of profitability, SPL.AX's ROE is -0.16%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, SPL.AX is more volatile compared to PAR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check PAR.AX's competition here
SPL.AX vs AVE.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, AVE.AX has a market cap of 71.2M. Regarding current trading prices, SPL.AX is priced at A$0.71, while AVE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas AVE.AX's P/E ratio is -16.90. In terms of profitability, SPL.AX's ROE is -0.16%, compared to AVE.AX's ROE of -3.70%. Regarding short-term risk, SPL.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check AVE.AX's competition here
SPL.AX vs PTX.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, PTX.AX has a market cap of 64.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while PTX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas PTX.AX's P/E ratio is -6.71. In terms of profitability, SPL.AX's ROE is -0.16%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, SPL.AX is more volatile compared to PTX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check PTX.AX's competition here
SPL.AX vs BIO.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BIO.AX has a market cap of 60.4M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BIO.AX trades at A$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BIO.AX's P/E ratio is 63.10. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, SPL.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check BIO.AX's competition here
SPL.AX vs ENP.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ENP.AX has a market cap of 52.2M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, SPL.AX is more volatile compared to ENP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ENP.AX's competition here
SPL.AX vs IMU.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, IMU.AX has a market cap of 47.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while IMU.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas IMU.AX's P/E ratio is -0.84. In terms of profitability, SPL.AX's ROE is -0.16%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, SPL.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check IMU.AX's competition here
SPL.AX vs RAD.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, RAD.AX has a market cap of 44.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas RAD.AX's P/E ratio is -0.92. In terms of profitability, SPL.AX's ROE is -0.16%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, SPL.AX is more volatile compared to RAD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check RAD.AX's competition here
SPL.AX vs BOT.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BOT.AX has a market cap of 37.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BOT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BOT.AX's P/E ratio is -0.56. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, SPL.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check BOT.AX's competition here
SPL.AX vs NOX.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, NOX.AX has a market cap of 26.7M. Regarding current trading prices, SPL.AX is priced at A$0.71, while NOX.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas NOX.AX's P/E ratio is -4.64. In terms of profitability, SPL.AX's ROE is -0.16%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, SPL.AX is more volatile compared to NOX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check NOX.AX's competition here
SPL.AX vs LCT.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, SPL.AX is priced at A$0.71, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, SPL.AX's ROE is -0.16%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, SPL.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check LCT.AX's competition here
SPL.AX vs MEM.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, MEM.AX has a market cap of 20.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas MEM.AX's P/E ratio is -3.10. In terms of profitability, SPL.AX's ROE is -0.16%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, SPL.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check MEM.AX's competition here
SPL.AX vs KZA.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, SPL.AX's ROE is -0.16%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, SPL.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check KZA.AX's competition here
SPL.AX vs NSB.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, NSB.AX has a market cap of 18.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while NSB.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas NSB.AX's P/E ratio is -3.88. In terms of profitability, SPL.AX's ROE is -0.16%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, SPL.AX is more volatile compared to NSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check NSB.AX's competition here
SPL.AX vs NC6.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, NC6.AX has a market cap of 17.5M. Regarding current trading prices, SPL.AX is priced at A$0.71, while NC6.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas NC6.AX's P/E ratio is -6.48. In terms of profitability, SPL.AX's ROE is -0.16%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, SPL.AX is more volatile compared to NC6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check NC6.AX's competition here
SPL.AX vs EZZ.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, EZZ.AX has a market cap of 17.4M. Regarding current trading prices, SPL.AX is priced at A$0.71, while EZZ.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas EZZ.AX's P/E ratio is 6.04. In terms of profitability, SPL.AX's ROE is -0.16%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, SPL.AX is more volatile compared to EZZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check EZZ.AX's competition here
SPL.AX vs 1AI.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, 1AI.AX has a market cap of 17.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, SPL.AX's ROE is -0.16%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, SPL.AX is less volatile compared to 1AI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check 1AI.AX's competition here
SPL.AX vs BTC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BTC.AX has a market cap of 17.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BTC.AX's P/E ratio is -20.75. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, SPL.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check BTC.AX's competition here
SPL.AX vs MDC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas MDC.AX's P/E ratio is -7.07. In terms of profitability, SPL.AX's ROE is -0.16%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, SPL.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check MDC.AX's competition here
SPL.AX vs BNO.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, SPL.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check BNO.AX's competition here
SPL.AX vs AGN.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, AGN.AX has a market cap of 12.3M. Regarding current trading prices, SPL.AX is priced at A$0.71, while AGN.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas AGN.AX's P/E ratio is -1.26. In terms of profitability, SPL.AX's ROE is -0.16%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, SPL.AX is more volatile compared to AGN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check AGN.AX's competition here
SPL.AX vs PAB.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, PAB.AX has a market cap of 11.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while PAB.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas PAB.AX's P/E ratio is -2.95. In terms of profitability, SPL.AX's ROE is -0.16%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, SPL.AX is more volatile compared to PAB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check PAB.AX's competition here
SPL.AX vs CMB.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, CMB.AX has a market cap of 9.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while CMB.AX trades at A$0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas CMB.AX's P/E ratio is -6.14. In terms of profitability, SPL.AX's ROE is -0.16%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, SPL.AX is more volatile compared to CMB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check CMB.AX's competition here
SPL.AX vs IMC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, IMC.AX has a market cap of 8.5M. Regarding current trading prices, SPL.AX is priced at A$0.71, while IMC.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas IMC.AX's P/E ratio is -1.77. In terms of profitability, SPL.AX's ROE is -0.16%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, SPL.AX is more volatile compared to IMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check IMC.AX's competition here
SPL.AX vs IXC.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, IXC.AX has a market cap of 6.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while IXC.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas IXC.AX's P/E ratio is -8.12. In terms of profitability, SPL.AX's ROE is -0.16%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, SPL.AX is more volatile compared to IXC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check IXC.AX's competition here
SPL.AX vs VBS.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, VBS.AX has a market cap of 6.7M. Regarding current trading prices, SPL.AX is priced at A$0.71, while VBS.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas VBS.AX's P/E ratio is -4.73. In terms of profitability, SPL.AX's ROE is -0.16%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, SPL.AX is more volatile compared to VBS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check VBS.AX's competition here
SPL.AX vs TRP.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, TRP.AX has a market cap of 6M. Regarding current trading prices, SPL.AX is priced at A$0.71, while TRP.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas TRP.AX's P/E ratio is -1.57. In terms of profitability, SPL.AX's ROE is -0.16%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, SPL.AX is more volatile compared to TRP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check TRP.AX's competition here
SPL.AX vs ZLD.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ZLD.AX's P/E ratio is -1.58. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, SPL.AX is more volatile compared to ZLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ZLD.AX's competition here
SPL.AX vs BGT.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BGT.AX has a market cap of 5.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BGT.AX's P/E ratio is -2.67. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, SPL.AX is less volatile compared to BGT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check BGT.AX's competition here
SPL.AX vs BIT.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, BIT.AX has a market cap of 4.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas BIT.AX's P/E ratio is -9.09. In terms of profitability, SPL.AX's ROE is -0.16%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, SPL.AX is less volatile compared to BIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check BIT.AX's competition here
SPL.AX vs ACR.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ACR.AX has a market cap of 4.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ACR.AX's P/E ratio is -1.09. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, SPL.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ACR.AX's competition here
SPL.AX vs RGS.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, SPL.AX is priced at A$0.71, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, SPL.AX's ROE is -0.16%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, SPL.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check RGS.AX's competition here
SPL.AX vs CYP.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, CYP.AX has a market cap of 3.4M. Regarding current trading prices, SPL.AX is priced at A$0.71, while CYP.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas CYP.AX's P/E ratio is -0.45. In terms of profitability, SPL.AX's ROE is -0.16%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, SPL.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check CYP.AX's competition here
SPL.AX vs CHM.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, CHM.AX has a market cap of 2.7M. Regarding current trading prices, SPL.AX is priced at A$0.71, while CHM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas CHM.AX's P/E ratio is -0.19. In terms of profitability, SPL.AX's ROE is -0.16%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, SPL.AX is less volatile compared to CHM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for SPL.AX.Check CHM.AX's competition here
SPL.AX vs ANR.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, SPL.AX is priced at A$0.71, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas ANR.AX's P/E ratio is -1.25. In terms of profitability, SPL.AX's ROE is -0.16%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, SPL.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check ANR.AX's competition here
SPL.AX vs EX1.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, SPL.AX is priced at A$0.71, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, SPL.AX's ROE is -0.16%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, SPL.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check EX1.AX's competition here
SPL.AX vs 1AD.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, 1AD.AX has a market cap of 1.8M. Regarding current trading prices, SPL.AX is priced at A$0.71, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas 1AD.AX's P/E ratio is -0.19. In terms of profitability, SPL.AX's ROE is -0.16%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, SPL.AX is more volatile compared to 1AD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check 1AD.AX's competition here
SPL.AX vs HXL.AX Comparison July 2026
SPL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPL.AX stands at 294.6M. In comparison, HXL.AX has a market cap of 542.9K. Regarding current trading prices, SPL.AX is priced at A$0.71, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPL.AX currently has a P/E ratio of 111.11, whereas HXL.AX's P/E ratio is -0.58. In terms of profitability, SPL.AX's ROE is -0.16%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, SPL.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for SPL.AX.Check HXL.AX's competition here